Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion

Abstract

These findings suggest that Cal and Bet have different effects on T cells to normalize psoriatic changes, with decreased TH17 cell expansion in the skin lesions.

Inhibition of IL-17–committed T cells in a murine psoriasis model by a vitamin D analogue

“…The CAL-mediated inhibition of T17 cell accumulation in human psoriatic lesions has recently been implicated by analyses using the ex vivo expansion of skin-infiltrating T cells with anti-CD3/CD28 antibodies and IL-2. 74 Our results obtained by means of unbiased identification of T17 cells in skin corroborate the in vivo suppressive effect of topical CAL on T17 cell accumulation in psoriatic lesions. In addition, we found that topical CAL application suppresses the expansion of T17 cells in the dLNs and leads to concomitant amelioration of psoriasis-like inflammation at a distant untreated site.…”

Vitamin D and the Pathophysiology of Inflammatory Skin Diseases

“…It was shown that vitamin D treatment impairs the capacity of pDCs to induce T-cell proliferation and IFN-γ secretion [79]. Vitamin D is also supposed to affect the Th17 pathway: it was observed that application of vitamin D and its analogs on psoriatic lesions significantly decreased the infiltration of Th17 cells in the skin and inhibited their ex vivo expansion [80,81]. In other studies, vitamin D was reported to suppress inflammatory cytokines like IL-12/23 p40, IL-1α, IL-1β, and TNF-α, which were present in abnormally high levels in psoriatic skin [82,83].…”

The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells

“…Vitamin D3 analogues are widely used to treat psoriasis, and the mechanisms underlying their therapeutic effectiveness have been studied mainly in keratinocytes, T cells and conventional DCs . pDCs play a triggering role in psoriatic lesions, but it is not known whether or how vitamin D3 analogues affect pDCs.…”